19 episodes

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerVoice Endocrinology & Metabolic Disorders Audio PeerVoice

    • Science

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors

    New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors

    Go online to peervoice.com/QTK860 to view the entire programme with slides. After completing “New Targets in Heart Failure: Congress Updates on SGLT2 Inhibitors”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with heart failure (HF); Analyse clinical evidence for safety and efficacy of medical therapy such as SGLT2 inhibitors in patients with HF; and Describe the potential clinical implications of novel strategies on outcomes in HF.

    • 12 min
    Evaluating the Evidence for SGLT2 Inhibition in CKD

    Evaluating the Evidence for SGLT2 Inhibition in CKD

    Go online to peervoice.com/QSX860 to view the entire programme with slides. After completing “Evaluating the Evidence for SGLT2 Inhibition in CKD”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

    • 19 min
    Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?

    Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?

    Go online to peervoice.com/YZK860 to view the entire programme with slides. After completing “Halting the Cascade of Chronic Kidney Disease: Can We Catch Patients Before They Fall?”, participants will be able to: Explain the rationale for SGLT2 inhibition in patients with chronic kidney disease (CKD), based on mechanisms of action; Analyse clinical evidence for safety and efficacy of oral therapy such as SGLT2 inhibitors in patients with CKD; and Describe the potential clinical implications of novel strategies on outcomes in CKD.

    • 36 min
    Managing Youth-Onset Type 2 Diabetes: What Paediatricians Need to Know

    Managing Youth-Onset Type 2 Diabetes: What Paediatricians Need to Know

    Managing Youth-Onset Type 2 Diabetes: What Paediatricians Need to Know

    • 19 min
    Hiding in Plain Sight: Identifying Patients at Risk for NASH

    Hiding in Plain Sight: Identifying Patients at Risk for NASH

    Hiding in Plain Sight: Identifying Patients at Risk for NASH

    • 24 min
    Managing Complicated Cases in Type 2 Diabetes

    Managing Complicated Cases in Type 2 Diabetes

    Managing Complicated Cases in Type 2 Diabetes

    • 14 min

Top Podcasts In Science

Listeners Also Subscribed To

More by PeerVoice